▟ Vinebot intrinsic value, daily

← back

HUM Humana

healthcare · valued with opus low conviction · deep-dived 2026-10-30

STRONG BUY
Intrinsic value$400.76
Price (at call)$417.56
Margin of safety -4.0%
vs market (rating basis) +42.5%

A Medicare Advantage giant in a margin trough; the price already assumes a partial recovery, so there is little cushion.

The story

Humana is the second-largest Medicare Advantage insurer, with a CenterWell primary care, pharmacy and home health platform that gives it real scale and some integration advantages in a growing senior market. Since 2023, rising medical utilization, V28 risk-adjustment cuts and star-rating losses have pushed operating margins from 4.3% to about 1.6%. It is a mature, scaled business in a cyclical trough, and what it is worth depends on whether MA pricing discipline and star recovery bring margins back to normal levels.

Senior demographics, the 2026 benefit repricing and modest membership gains support high-single-digit growth that fades to 3.5%. Margins recover over five years to about 3.7%, near the long-run managed-care average of 4-5% but discounted for permanently tighter MA risk adjustment and Humana's concentration in government programs. The insurer's light capital needs support a sales-to-capital ratio of about 4.5, and beta sits slightly above the 0.9 industry anchor because of policy exposure. Margins staying at today's 1.6% would justify the baseline value of about $107 instead of the current price.

Value drivers

Revenue growth (Y1)8.0%
Terminal growth3.5%
Forecast horizon8y
Target operating margin3.7%
Years to target margin5
Sales-to-capital4.50
Beta0.95
Failure probability2.0%
Cost of capital (WACC)8.7%
Terminal WACC8.9%

Valuation bridge

PV of explicit FCFF15.08B
PV of terminal value42.27B
Equity value48.12B
÷ shares → per share$400.76

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 157.33B 8.0% 2.0% 2.70B 2.59B 108.61M 99.92M
2 168.91B 7.4% 2.5% 3.48B 2.57B 911.68M 771.58M
3 180.25B 6.7% 2.9% 4.34B 2.52B 1.82B 1.42B
4 191.19B 6.1% 3.3% 5.27B 2.43B 2.84B 2.03B
5 201.57B 5.4% 3.7% 6.26B 2.31B 3.95B 2.60B
6 211.22B 4.8% 3.7% 6.56B 2.14B 4.41B 2.68B
7 219.97B 4.1% 3.7% 6.83B 1.94B 4.89B 2.72B
8 227.67B 3.5% 3.7% 7.07B 1.71B 5.36B 2.75B

Key risks

  • Medical cost trends keep outrunning pricing, so margins stay stuck near 2%
  • Star-rating downgrades and CMS rate notices or V28 risk-adjustment changes cut payments
  • Political or regulatory moves against Medicare Advantage overpayment and coding intensity

Catalysts

  • Star ratings recover for 2027 payments, restoring bonus revenue
  • Favorable 2027 CMS final rate notice plus margin-first bid discipline showing up in EPS

History

DatePriceIntrinsicMoSRating
2026-10-30$417.56 $400.76 -4.0% STRONG BUY
2026-09-10$400.02 $113.10 -71.7% SELL
2026-07-22$404.34 $398.78 -1.4% STRONG BUY
2026-07-21$398.20 $82.21 -79.4% N/A
2026-06-23$359.13 $302.90 -15.7% STRONG BUY